Aarti Drugs Limited (NSE:AARTIDRUGS) — Market Cap & Net Worth
Market Cap & Net Worth: Aarti Drugs Limited (AARTIDRUGS)
Aarti Drugs Limited (NSE:AARTIDRUGS) has a market capitalization of $365.36 Million (Rs33.78 Billion) as of June 19, 2026. Listed on the NSE stock exchange, this India-based company holds position #13980 globally and #698 in its home market, demonstrating a -0.47% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aarti Drugs Limited's stock price Rs370.15 by its total outstanding shares 91270000 (91.27 Million). Review Aarti Drugs Limited (AARTIDRUGS) financial obligations to assess the company's total debt and financial obligations.
Aarti Drugs Limited Market Cap History: 2015 to 2026
Aarti Drugs Limited's market capitalization history from 2015 to 2026. Data shows growth from $141.74 Million to $365.36 Million (9.20% CAGR).
Index Memberships
Aarti Drugs Limited is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY MIDSMALLCAP 400
NIFTYMIDSML400
|
$1.15 Trillion | 0.03% | #314 of 400 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$3.24 Trillion | 0.01% | #515 of 750 |
Weight: Aarti Drugs Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Aarti Drugs Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aarti Drugs Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
Aarti Drugs Limited's market cap is 0.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.24x
Aarti Drugs Limited's market cap is 0.24 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $145.58 Million | $11.35 Billion | $687.25 Million | 0.01x | 0.21x |
| 2017 | $154.43 Million | $11.95 Billion | $805.63 Million | 0.01x | 0.19x |
| 2018 | $140.13 Million | $12.44 Billion | $823.07 Million | 0.01x | 0.17x |
| 2019 | $141.06 Million | $15.61 Billion | $897.51 Million | 0.01x | 0.16x |
| 2020 | $691.59 Million | $18.06 Billion | $1.41 Billion | 0.04x | 0.49x |
| 2021 | $534.42 Million | $21.55 Billion | $2.80 Billion | 0.02x | 0.19x |
| 2022 | $452.12 Million | $24.89 Billion | $2.05 Billion | 0.02x | 0.22x |
| 2023 | $481.94 Million | $27.16 Billion | $1.66 Billion | 0.02x | 0.29x |
| 2024 | $454.44 Million | $25.29 Billion | $1.71 Billion | 0.02x | 0.27x |
| 2025 | $406.32 Million | $23.87 Billion | $1.68 Billion | 0.02x | 0.24x |
Competitor Companies of AARTIDRUGS by Market Capitalization
Companies near Aarti Drugs Limited in the global market cap rankings as of June 19, 2026.
Key companies related to Aarti Drugs Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #555 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #601 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #555 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #601 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.30 |
Aarti Drugs Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Aarti Drugs Limited's market cap moved from $141.74 Million to $ 365.36 Million, with a yearly change of 9.20%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs365.36 Million | -10.08% |
| 2025 | Rs406.32 Million | -10.59% |
| 2024 | Rs454.44 Million | -5.71% |
| 2023 | Rs481.94 Million | +6.60% |
| 2022 | Rs452.12 Million | -15.40% |
| 2021 | Rs534.42 Million | -22.73% |
| 2020 | Rs691.59 Million | +390.28% |
| 2019 | Rs141.06 Million | +0.67% |
| 2018 | Rs140.13 Million | -9.26% |
| 2017 | Rs154.43 Million | +6.07% |
| 2016 | Rs145.58 Million | +2.71% |
| 2015 | Rs141.74 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Aarti Drugs Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $365.36 Million USD |
| MoneyControl | $365.36 Million USD |
| MarketWatch | $365.36 Million USD |
| marketcap.company | $365.36 Million USD |
| Reuters | $365.36 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Aarti Drugs Limited
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enro… Read more